Related Experiment Videos

The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice

Owen J Sansom1, Alan R Clarke

  • 1Cardiff School of Biosciences, University of Cardiff, CF10 3US, UK.

Oncogene
|August 20, 2002
PubMed

Insights

Investigating p53 and Msh2 gene roles in mouse intestinal cells revealed that while p53 deficiency blocked immediate apoptosis, it only improved survival after cisplatin. Msh2 deficiency impacted apoptosis and crypt survival differently depending on the cytotoxic agent.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • The tumor suppressor protein p53 and the DNA mismatch repair protein Msh2 play critical roles in cellular responses to DNA damage.
  • Understanding their interplay is crucial for predicting outcomes of genotoxic cancer therapies.

Purpose of the Study:

  • To investigate the roles of p53 and Msh2 in apoptosis and enterocyte survival following exposure to cytotoxic agents.
  • To determine if genetic status influences long-term crypt survival in vivo.

Main Methods:

  • In vivo study using mice singly or doubly mutant for p53 and Msh2.
  • Exposure to cytotoxic agents: Cisplatin, Nitrogen Mustard, and N-methyl-N-nitrosourea (NMNU).
  • Assessment of apoptosis and long-term enterocyte (crypt) survival.

Main Results:

  • p53 deficiency abrogated immediate apoptosis but only increased survival after cisplatin.
  • Msh2 deficiency reduced apoptosis and increased crypt survival after NMNU.
  • A delayed apoptosis wave, independent of Mismatch Repair (MMR), was observed in p53-deficient mice.
  • Combined Msh2 and p53 deficiency mirrored p53 deficiency responses.

Conclusions:

  • Loss of p53 or Msh2-dependent apoptosis does not predict long-term crypt survival.
  • Genetic status significantly modulates survival in response to specific cytotoxic agents like cisplatin.

Related Concept Videos